PODD stock forecast: what analysts expect
Wall Street analysts covering Insulet Corporation currently rate the stock a Buy on average, with a mean 12-month price target of $171.91 — +20.2% versus the last price of $143.05. Targets reflect analyst opinion, not a guarantee.
PODD historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in PODD.
PODD annual returns by year
Congress trading in PODD
3 members of Congress have disclosed trading PODD — 2 purchases and 3 sales worth an estimated $40,000. Most recent disclosure: Feb 16, 2021.
Insider activity in PODD
PODD's own executives and directors have made 3 open-market purchases ($1.1M) and 1 sale ($59,887) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 21, 2026.
| Aug 21, 2026 | McEvoy Ashley | President and CEO | Buy | $162,217 |
| Jun 3, 2026 | Stonesifer Timothy C. | Director | Buy | $400,393 |
| Jun 3, 2026 | Borio Luciana | Director | Sell | $59,887 |
| Jun 3, 2026 | Weatherman Elizabeth H | Director | Buy | $497,490 |
About Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
PODD Key Statistics
PODD in plain English
- P/E ratio (27.2) — how many dollars you pay for each $1 of PODD's yearly profit. That's a fairly normal range.
- ROE (26.02%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (12.29%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend — PODD doesn't pay a meaningful dividend; the return here comes from the share price, not cash payouts.
PODD stock: frequently asked questions
What is Insulet Corporation's stock price today?
Insulet Corporation (PODD) last traded at $143.05 on the NASDAQ. Over the past 52 weeks the stock has traded between $126.40 and $354.88.
Is PODD stock a buy or a sell?
Wall Street analysts' consensus rating on PODD is "Buy", with an average 12-month price target of $171.91 — about +20.2% versus the current price of $143.05. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in PODD 10 years ago be worth today?
A $1,000 investment in Insulet Corporation made 10 years ago would be worth about $3,379 today (dividends reinvested) — a total return of 238%, or 13.0% per year.
Does PODD pay a dividend?
No — Insulet Corporation does not currently pay a meaningful dividend. Returns for shareholders come from changes in the share price.
What is PODD's P/E ratio?
PODD trades at a trailing price-to-earnings ratio of 27.2, and 18.6 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade PODD stock?
Yes — 3 members of Congress have disclosed trades in PODD under the STOCK Act, totaling 2 purchases and 3 sales worth an estimated $40,000.
What is Insulet Corporation's ticker symbol?
Insulet Corporation trades under the ticker symbol PODD on the NASDAQ.
Compare PODD with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.